Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Hurwitz

Showing results (91-100 of 182) with videos related to

Pageof 19
Sort By:
Cancer Chemotherapy and Pharmacology|October 26, 2010
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumorsCarlos Castaneda, Kellen L Meadows, Roxanne Truax, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)Andrew B Nixon, Herbert Pang, Mark D Starr, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2014
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort studyAxel Grothey, E Dawn Flick, Allen L Cohn, et al.
Cancer Medicine|February 28, 2014
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancerYingmiao Liu, Mark D Starr, John C Brady, et al.
Cancers|May 14, 2022
Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal CancerStephanie J Yaung, Christine Ju, Sandeep Gattam, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2007
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancerChris R Kelsey, Junzo P Chino, Christopher G Willett, et al.
International Journal of Radiation Oncology, Biology, Physics|July 2, 2005
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experienceBrian G Czito, Herbert I Hurwitz, Robert W Clough, et al.
Anticancer Research|June 10, 2010
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumorsElizabeth Dugan, Roxanne Truax, Kellen L Meadows, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2015
Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound HealingJingquan Jia, Andrew E Dellinger, Eric S Weiss, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2015
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man studyHerbert I Hurwitz, David C Smith, Henry C Pitot, et al.
Pageof 19

Showing results (91-100 of 182) with videos related to

Sort By:
Pageof 19
Cancer Chemotherapy and Pharmacology|October 26, 2010
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumorsCarlos Castaneda, Kellen L Meadows, Roxanne Truax, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)Andrew B Nixon, Herbert Pang, Mark D Starr, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2014
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort studyAxel Grothey, E Dawn Flick, Allen L Cohn, et al.
Cancer Medicine|February 28, 2014
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancerYingmiao Liu, Mark D Starr, John C Brady, et al.
Cancers|May 14, 2022
Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal CancerStephanie J Yaung, Christine Ju, Sandeep Gattam, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2007
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancerChris R Kelsey, Junzo P Chino, Christopher G Willett, et al.
International Journal of Radiation Oncology, Biology, Physics|July 2, 2005
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experienceBrian G Czito, Herbert I Hurwitz, Robert W Clough, et al.
Anticancer Research|June 10, 2010
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumorsElizabeth Dugan, Roxanne Truax, Kellen L Meadows, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2015
Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound HealingJingquan Jia, Andrew E Dellinger, Eric S Weiss, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2015
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man studyHerbert I Hurwitz, David C Smith, Henry C Pitot, et al.
Pageof 19